Insider Financial

Receive Real-Time Short-Term Momentum Stock Alerts

No spam. No Hidden Fees. Unsubscribe Anytime.

Cannabis

GenVec Inc (NASDAQ:GNVC) Is Another Low Float Runner

Low floats have been the name of the game for a number of biotech companies this week, with some seemingly inexplicable runs only explained by low float, high-volume spikes. Here is another one. The company is GenVec Inc (NASDAQ:GNVC), and it is currently trading at a 114% premium to its weekly open price. As has been the case with the other companies in this category, there has been no real fundamental development of note, and nothing is registering as freshly filed with the SEC. This hasn’t stopped us from taking interest in these sorts of runs in the past, however, so let’s do the same with GenVec, in an attempt to figure out what’s next.

This one is a development stage biotechnology company based out of Maryland. Its headline focus is on the development of therapies using what is called adenoviral-based technology. The company’s lead technology, a gene delivery platform, takes its name from this broad spectrum description, and is called AdenoVerse Technology. The science behind it is relatively simple in concept. Basically, the company is trying to undertake gene editing as a way to treat certain conditions, but these genes need a delivery vehicle through which they can reach their target cells. With the AdenoVerse technology, GenVec employs an adenovirus as its vector (with vector here just meaning the delivery vehicle). These types of vectors can be altered to deliver large or multigene payloads and – perhaps most importantly – avoid pre-existing immunity. In other words, our immune system won’t attack them on introduction.

Right now, the company’s lead application of this technology is a drug called CGF166, which is currently under investigation for the treatment of hearing loss. The drug is in a phase 1/2 study, but suffered a setback early last year, when GenVec’s partner on the study, biotech giant Novartis AG (ADR) (NYSE:NVS), informed the company that the FDA had placed a clinical hold on the investigation. After a review by the trial’s Data Safety Monitoring Board (DSMB), this clinical hold lifted in July, and the study got back underway. Since then, core focus has been rooted in an attempt to catch up on the lost time from an enrollment perspective, and – if the two companies’ latest releases are anything to go by – this has been achieved. The study is set to complete at some point during 2017 (likely later on this year, as opposed to earlier) and that is the next real impactful catalyst from a GenVec perspective.

The company undertook a reverse split early December, utilizing a 1 for 10 ratio, and while these sorts of maneuvers are generally regarded as negative at this end of the biotech space, it seems to have done GenVec some good. The company has managed to maintain its above bid price, and with the recent gains in place, is now trading above the magic $5 mark, putting it on the radar of a large number of institutional investors. We see any announcement related to smart money taking a 5% plus position over the coming quarter as a near-term, non-data related catalyst.

A just signed Washington University agreement has also served to buoy sentiment somewhat, and should help to establish a number of expanded therapeutic areas for GenVec’s AdenoVerse tech heading into the next couple of quarters.

As ever, cash on hand isn’t great, but it’s not terrible either. At September 30, 2016, the company reported cash at a little under $5 million and zero debt. Couple this with the potential for some near-term institutional capital injections, and there’s every chance that the gains seen over the last week or so will continue into the close of the first quarter and beyond.

A low float gainer for sure, but one that has drawn attention to an undervalued entity, and this attention could – in turn – draw some speculative near term buy volume.

We will be updating our subscribers as soon as we know more. For the latest updates on GNVC, sign up below!

Sign up for next microcap runner ahead of the crowd.

Disclosure: We have no position in GNVC and have not been compensated for this article.

GET NOTIFIED
Sign up for our next MicroCap Runner ahead of the crowd!
We hate spam. No Hidden Fees. Unsubscribe Anytime.
GenVec Inc (NASDAQ:GNVC) Is Another Low Float Runner
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Enter Symbol For Report



For over five years, we have provided a free service to a countless number of traders featuring only the best in the microcap arena. Insider Financial focuses solely on short-term high probability trade opportunities.

Our alerts consist of Nasdaq, NYSE and high quality OTC companies that are capable of delivering outsized gains to you today, not a year from now. If you have an interest in the lucrative microcap sector, sign up to Insider Financial today!

GET NOTIFIED
Sign up for our next MicroCap Runner ahead of the crowd!
We hate spam. No Hidden Fees. Unsubscribe Anytime.

Copyright © 2017 Insider Financial powered by Hundred.

To Top

Sign up now for our FREE Small Cap Newsletter

Sign up now for our FREE Small Cap Newsletter